Abstract 348P
Background
Effective interventions to improve prognosis in non-small-cell lung cancer (NSCLC) are urgently needed. We assessed the effect of the early integration of interdisciplinary palliative care for patients with NSCLC on the nutritional status, quality of life (QoL), psychological state and cancer pain.
Methods
In this randomised controlled trial, 120 newly diagnosed NSCLC patients were enrolled and randomly assigned (1:1) to the combined early palliative care (CEPC) group integrated with standard oncologic care or standard oncological care (SC) group. QoL and psychological state were assessed at baseline and at 24 weeks by Functional Assessment of Cancer Therapy-Lung (FACT-L) scale, the Hospital Anxiety and Depression Scale (HADS) and Patient Health Questionnaire-9 (PHQ-9), respectively. Cancer nutritional and pain status were assessed with the use of the Patient-Generated Subjective Global Assessment (PG-SGA) and Numerical Rating Scale (NRS), respectively. The primary outcome was the change in the quality of life, psychological state and nutritional status at 24 weeks. Analysis was by intention to treat.
Results
120 patients were enrolled: 60 in CEPC group (38 completed) and 60 in the SC group(32 completed). Patients in CEPC group had a better nutritional status [severe malnutrition: 11.67% (7/60); mild or moderate malnutrition: 61.67% (37/60); no malnutrition: 26.67% (16/60)] than SC group[severe malnutrition: 36.67% (22/60); mild or moderate malnutrition: 55.0% (33/60); no malnutrition: 8.3% (5/60)] (P=0.001). Furthermore, CEPC group had a better QoL than SC group (P<0.05). In addition, fewer patients in the CEPC group than in the SC group had depressive (P=0.005) symptoms. There was no significant difference in NRS score between CEPC group and SC group.
Conclusions
Among patients with non-small-cell lung cancer, early palliative care led to significant improvements in nutritional status, quality of life and psychological state.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
343P - Immunotherapy as first-line treatment in metastatic non-small cell lung cancer: A single center experience
Presenter: Harshitha N.J
Session: Poster viewing 05.
344P - Loco-regional radiotherapy (RT) in M1a non-small cell lung cancer (NSCLC) downstaged with chemotherapy (CT)
Presenter: Hegde Adarsh Gajanan
Session: Poster viewing 05.
345P - First-line gemcitabine-platinum chemotherapy in relapsed or metastatic pulmonary lymphoepithelioma-like carcinoma: A tertiary centre experience
Presenter: Gavin Tin Chun Cheung
Session: Poster viewing 05.
346P - The safety and efficacy of intrathecal chemotherapy with pemetrexed via the Ommaya reservoir for leptomeningeal metastases from lung adenocarcinoma: A prospective study
Presenter: Huiying Li
Session: Poster viewing 05.
347P - Real-world efficacy of first-line therapy in wild-type non-small cell lung cancer (NSCLC) patients with brain metastases
Presenter: Benjamin Kong
Session: Poster viewing 05.
349P - EXPLORE-LC: A multi-site real-world evidence research platform for non-small cell lung cancer in Asia-Pacific
Presenter: Kong Chian Toh
Session: Poster viewing 05.
350P - Primary prevention of chemotherapy-induced neutropenia in patients with advanced lung cancer in real-world research
Presenter: ZHEN ZENG
Session: Poster viewing 05.
351P - Real-world study of herombopag in primary prevention and treatment of chemotherapy-induced thrombocytopenia (CIT) in advanced lung cancer
Presenter: Haifeng Qin
Session: Poster viewing 05.
352P - Impact of novel agent therapy on survival of patients with advanced non-small cell lung cancer in Lebanon
Presenter: Marcel Massoud
Session: Poster viewing 05.
353P - Effect of cepharanthine on the stemness of lung squamous cell carcinoma based on network pharmacology and bioinformatics
Presenter: Jianxiong Deng
Session: Poster viewing 05.